Background In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin
signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional …

Pulmonary arterial hypertension (PAH) is a progressive disease that results in right
ventricular (RV) dysfunction and increased pulmonary artery pressure (PAP), caused by …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept
resulted in a significantly greater reduction from baseline in pulmonary vascular resistance …

Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Introduction Pulmonary arterial hypertension (PAH) is a rare, progressive disease
associated with significant morbidity and mortality. The phase 3 STELLAR trial tested …

Rationale: There are no direct comparisons of sotatercept to add-on therapies approved for
PAH. Objective: This study aimed to compare the efficacy and safety of add-on sotatercept …

Sotatercept, a soluble fusion protein comprising the extracellular domain of activin receptor
type IIA linked to the Fc portion of human IgG1, is a first‐in‐class activin signaling inhibitor …

Background Data obtained in human lung tissue and preclinical models suggest that
oxidative stress and increased apoptosis signal-regulating kinase 1 (ASK1) activity might …

Pulmonary hypertension due to left heart disease (PH-LHD) is the most frequent
manifestation of PH but lacks any approved treatment. Activin receptor type IIA Fc-fusion …